Key clinical point: The strategy of rapid alteration of drugs to overcome imatinib resistance mutation in gastrointestinal stromal tumor (GIST) is feasible but was ineffective.
Major finding: There were no objective responses among 12 patients treated continuously with 3 days of sunitinib (Sutent) followed by 4 days of regorafenib (Stivarga). Although four patients had stable disease in the short term, in each case the disease progressed within 16 weeks.
Study details: Phase Ib clinical trial in 12 patients with heavily pre-treated metastatic GIST.
Disclosures: The study was supported by an ASCO Young Investigator Award, Pfizer, and Bayer. Dr. Serrano disclosed honoraria from Bayer, a consulting or advisory role for Deciphera, research funding from Bayer and Deciphera, and travel accommodations and expenses from Pfizer.
Source: Serrano C et al. ASCO 2018 Abstract 11510.
Serrano C et al. ASCO 2018 Abstract 11510.
This Week's Must Reads
Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894
For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035
Concerns rise over proposal by CMS to level E/M payments , CMS proposed rule, CMS-1693-P
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824
Must Reads in Sarcoma & GIST
Liquid biopsy aids assessment in advanced imatinib-resistant GIST, George S et al. ASCO 2018. Abstract 11511.
Rapid therapy changes fall short for metastatic GIST, Serrano-Garcia C et al. ASCO 2018, Abstract 11510.
Adjuvant doxorubicin and ifosfamide boost outcomes in soft tissue sarcomas, Pasquali S et al. ASCO 2018, Abstract 115118.
Two novel TKIs better than one in GIST with multiple KIT mutations, Wagner AJ et al. ASCO 2018, Abstract 11509.
PFS better with trofosfamide than doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomas, Hartman JT et al. ASCO 2018, Abstract 11507.